D. J. Torok

Jeffrey R. Stout; Joel T. Cramer; Robert F. Zoeller; D. J. Torok; P. Costa; Jay R. Hoffman; Roger C. Harris; J. O’Kroy

Summary.This study examined the effects of 28 days of β-alanine supplementation on the physical working capacity at fatigue threshold (PWCFT), ventilatory threshold (VT), maximal oxygen consumption (

Jeffrey R. Stout; Joel T. Cramer; Michelle Mielke; Joseph A. O'kroy; D. J. Torok; Robert F. Zoeller

\dot{\rm V}

Robert F. Zoeller; J. R. Stout; J. O’Kroy; D. J. Torok; Michelle Mielke

O2-MAX), and time-to-exhaustion (TTE) in women. Twenty-two women (age ± SD 27.4 ± 6.1 yrs) participated and were randomly assigned to either the β-alanine (CarnoSyn™) or Placebo (PL) group. Before (pre) and after (post) the supplementation period, participants performed a continuous, incremental cycle ergometry test to exhaustion to determine the PWCFT, VT,

Ava J. Walker; David R. Bassett; W. J. Duey; Edward T. Howley; Vernon Bond; D. J. Torok; P. Mancuso

\dot{\rm V}

W. J. Duey; David R. Bassett; D. J. Torok; Edward T. Howley; Vernon Bond; P. Mancuso; R. Trudell

O2-MAX, and TTE. There was a 13.9, 12.6 and 2.5% increase (p < 0.05) in VT, PWCFT, and TTE, respectively, for the β-alanine group, with no changes in the PL (p > 0.05). There were no changes for

M. Allison Ford; D. J. Torok

\dot{\rm V}

Joseph A. O'kroy; Todd James; Joshua M. Miller; D. J. Torok; Katherine Campbell

O2-MAX (p > 0.05) in either group. Results of this study indicate that β-alanine supplementation delays the onset of neuromuscular fatigue (PWCFT) and the ventilatory threshold (VT) at submaximal workloads, and increase in TTE during maximal cycle ergometry performance. However, β-alanine supplementation did not affect maximal aerobic power (

William J. Duey; David R. Bassett; Ava J. Walker; D. J. Torok; Edward T. Howley; Daniel Ely; Mark O. Pease

\dot{\rm V}

D. J. Torok; W. J. Duey; David R. Bassett; Edward T. Howley; Peter Mancuso

O2-MAX). In conclusion, β-alanine supplementation appears to improve submaximal cycle ergometry performance and TTE in young women, perhaps as a result of an increased buffering capacity due to elevated muscle carnosine concentrations.

Bonita L. Marks; Laurence M. Katz; Jerome E. Haky; W. M. Foss; D. J. Torok

The purpose of this study was to examine the effects of 28 days of beta-alanine (b-Ala) and creatine monohydrate (CrM) supplementation on the onset of neuromuscular fatigue by using the physical working capacity at neuromuscular fatigue threshold (PWCFT) test in untrained men. Fifty-one men (mean age ± SD = 24.5 ± 5.3 years) volunteered to participate in this 28-day, double-blind, placebo-controlled study and were randomly assigned to 1 of 4 groups: placebo (PLA; 34 g dextrose; n = 13), CrM (5.25 g CrM plus 34 g dextrose; n = 12), b-Ala (1.6 g b-Ala plus 34 g of dextrose; n = 12), or b-Ala plus CrM (CrBA; 5.25 g CrM plus 1.6 g b-Ala plus 34 g dextrose; n = 14). The supplement was ingested 4 times per day for 6 consecutive days, then twice per day for 22 days before posttesting. Before and after the supplementation, subjects performed a continuous incremental cycle ergometry test while a surface electromyographic signal was recorded from the vastus lateralis muscle to determine PWCFT. The adjusted mean posttest PWCFT values (covaried for pretest PWCFT values) for the b-Ala and CrBA groups were greater than those for the PLA group (p ≤ 0.05). However, there were no differences between the CrM vs. PLA, CrBA vs. b-Ala, CrM vs. b-Ala, or CrM vs. CrBA groups (p > 0.05). These findings suggested that b-Ala supplementation may delay the onset of neuromuscular fatigue. Furthermore, there appeared to be no additive or unique effects of CrM vs. b-Ala alone on PWCFT.